Compare NSYS & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NSYS | SCLX |
|---|---|---|
| Founded | 1981 | 2011 |
| Country | United States | United States |
| Employees | N/A | 34 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.1M | 34.4M |
| IPO Year | 1996 | 2020 |
| Metric | NSYS | SCLX |
|---|---|---|
| Price | $11.42 | $4.93 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 15.3K | ★ 28.1K |
| Earning Date | 05-13-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.85 | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | $14,371,000.00 | ★ $30,253,000.00 |
| Revenue This Year | N/A | $122.52 |
| Revenue Next Year | N/A | $186.30 |
| P/E Ratio | $124.78 | ★ N/A |
| Revenue Growth | ★ 7.01 | N/A |
| 52 Week Low | $6.50 | $4.20 |
| 52 Week High | $18.01 | $29.84 |
| Indicator | NSYS | SCLX |
|---|---|---|
| Relative Strength Index (RSI) | 41.26 | 35.89 |
| Support Level | $11.23 | $4.85 |
| Resistance Level | $12.21 | $5.60 |
| Average True Range (ATR) | 0.47 | 0.31 |
| MACD | 0.07 | 0.04 |
| Stochastic Oscillator | 22.80 | 7.81 |
Nortech Systems Inc is a United States-based electronic manufacturing services company. It offers value-added engineering, technical, and manufacturing services and support, including project management, design, testing, prototyping, manufacturing, supply chain management, and post-market services. The company's manufacturing and engineering services include complete medical devices, printed circuit board assemblies, wire and cable assemblies, and complex higher-level electro-mechanical assemblies. It operates in the Medical, Aerospace, Defense, and Industrial markets, with key revenue coming from medical-related markets.
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.